Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2014 16:01 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Sells Priority Review Voucher for $67.5 Million

SAN RAFAEL, Calif., July 30, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that it has sold the Rare Pediatric Disease Priority Review Voucher (PRV) it obtained...
July 30, 2014 16:01 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces Second Quarter 2014 Financial Results

- VIMIZIM® Sales Top $14 million in First Full Quarter of Sales - Full Year Total BioMarin Revenue Guidance Increased Financial Highlights ($ in millions, except per share data,...
July 23, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

Sarah Cannon Research UK and BioMarin Collaborate on EMBRACA Clinical Study in Hereditary Breast Cancer With BRCA Mutation

SAN RAFAEL, Calif., July 23, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) and Sarah Cannon Research UK today announced a collaboration to enroll patients in an ongoing Phase 3...
July 09, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host Second Quarter 2014 Financial Results Conference Call and Webcast on Wednesday, July 30 at 4:30pm ET

SAN RAFAEL, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today...
June 10, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at the Wells Fargo Healthcare Conference on June 17th

SAN RAFAEL, Calif., June 10, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today...
May 27, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Doses First Patient in Phase 3 INSPIRE Trial With BMN 701 for the Treatment of Pompe Disease

SAN RAFAEL, Calif., May 27, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that it has dosed the first patient with BMN 701 (GILT-tagged Recombinant Human GAA) in...
May 06, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Present at the Bank of America Merrill Lynch 2014 Healthcare Conference on May 14th and the UBS Global Healthcare Conference on May 20th

SAN RAFAEL, Calif., May 6, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in the development and commercialization of therapies for rare genetic diseases, today...
May 01, 2014 16:05 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces First Quarter 2014 Financial Results and VIMIZIM(TM) Launch Progress

- Total BioMarin Revenue Grew 18.5% in 1Q14 - 50 Patients Receiving Commercial VIMIZIM as of April 30 - VIMIZIM Approved in the U.S. and E.U.; Commercial Launch Underway in both Regions - PEG...
April 28, 2014 11:06 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin Announces European Commission Approval for VIMIZIM(R) (elosulfase alfa) for the Treatment of Morquio A Syndrome in Patients of All Ages

SAN RAFAEL, Calif., April 28, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the European Commission has granted marketing authorization for VIMIZIM®...
April 16, 2014 08:00 ET | Source: BioMarin Pharmaceutical Inc.

BioMarin to Host First Quarter 2014 Financial Results Conference Call and Webcast on Thursday, May 1 at 5:00 p.m. ET

SAN RAFAEL, Calif., April 16, 2014 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that Jean-Jacques Bienaimé, Chief Executive Officer of BioMarin, will host a...